Blood biomarkers are changing the assay question
pTau, NfL, GFAP, and related markers are reshaping how translational teams think about sensitivity, matrix, and clinical context.
Insights for translational assay strategy
Short, practical perspectives on biomarker assays, diagnostics, AI biology, circRNA, and the scientific packaging needed to move programs forward.
AI makes generic research cheaper
The durable value shifts toward experimental credibility, judgment under ambiguity, data access, and cross-border trust.
Expression kinetics matter
circRNA programs need practical assays that connect expression, mechanism, delivery, and biomarker readouts.
Planned insight series
These topics support the reputation and narrative layer of the VexisBio strategy.
To-USA translational readiness checklist
How to evaluate whether an assay, biomarker, or therapeutic program is ready for U.S. partner discussion.
ELISA-qPCR platform differentiation
How high-sensitivity immunoassay architectures differ in chemistry, workflow, IP, and manufacturability.
Biomarker validation without overclaiming
How to describe analytical performance, research-use claims, and clinical next steps responsibly.
What AI cannot replace in assay development
Why real samples, real data, judgment, and reputation become more important as information gets cheaper.